WCN26-2649 EFFECT OF NAFAMOSTAT MESYLATE ON BRADYKININ PRODUCTION AND BLOOD PRESSURE STABILITY DURING LDL APHERESIS IN CHRONIC LIMB-THREATENING ISCHEMIA

Read full text Summarise with VIRAT
Authors: Yusuke Yoshimura, Takaya Handa, Susumu Tsunoda, Hisashi Sugimoto, Yoshifumi Ubara, Takehiko Wada, Takeshi Matsubara, Naoki Sawa
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

LDL apheresis is indicated for severe chronic limb-threatening ischemia (CLTI) refractory to revascularization. Negative charge of dextran sulfate in the apheresis column can activate the kallikrein–kinin system and induce bradykinin-mediated hypotension, compromising procedural safety. We investigated whether using the positively charged anticoagulant nafamostat mesylate (NM), instead of standard heparin (HP), could neutralize the dextran sulfate charge, suppress bradykinin production, and improve hemodynamic stability.

Fields of Study & Subjects

Coagulation Bradykinin Polyphosphates and Angioedema Peripheral Artery Disease Management Complement system in diseases

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106152–106152
Publication date
25 March 2026
Language
EN